Fate Therapeutics (FATE) Price & Analysis

Compare

1,225 Followers

FATE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.66 - $4.20

Previous CloseN/A

Volume630.90K

Average Volume (3M)1.47M

Market Cap

$110.23M

Enterprise Value-$8.74M

Total Cash (Recent Filing)$222.83M

Total Debt (Recent Filing)$81.33M

Price to Earnings (P/E)―

Beta2.67

Next Earnings

Oct 30, 2025

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding115,329,700

10 Day Avg. Volume1,436,980

30 Day Avg. Volume1,473,458

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.08

Enterprise Value/Revenue-1.03

Enterprise Value/Gross Profit-1.68

Enterprise Value/Ebitda0.05

Forecast

1Y Price Target

$4.21

Price Target Upside343.16% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical AdvancementsFT836 and FT839 are advancing toward clinical entry without the need for conditioning chemotherapy, showcasing innovation in treatment approaches.

Financial StabilityFATE has extended its cash runway through early 2028, indicating financial stability to support ongoing operations.

Positive Clinical Trial ResultsFate presented updated results for FT819 in SLE/LN at EULAR, which showed encouraging early clinical activity.

Bears Say

Regulatory And Partnership RisksRisks include, but are not limited to: unknown clinical efficacy advantage with FT522 relative to other allogeneic and autologous CAR-T approaches; unexpected safety and immunogenicity concerns; partnership-related risks; negative reactions from regulatory agencies; and possible medium-term dilution risk.

Safety ConcernsTwo patients had Grade 4 neutropenia and two patients had Grade 3+ infections.

Workforce ReductionThe company also disclosed a 12% reduction in workforce which further extends cash runway through 2027.

Fate Therapeutics News

Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors

Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Share Price & Shareholder Rights category. Fate...

1M ago

FATE

Fate Therapeutics Reports Q2 2025 Financial Results

Fate Therapeutics Inc ( ($FATE) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

FATE

Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo

Wells Fargo lowered the firm’s price target on Fate Therapeutics (FATE) to $2.50 from $4 and keeps an...

1M ago

FATE

Cautious Hold Rating for Fate Therapeutics Amid Developmental and Regulatory Uncertainties

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating yesterday. Gil...

1M ago

FATE

Cautious Hold Rating on Fate Therapeutics Amid Promising CAR-iT Developments and Early Stage Trials

TD Cowen analyst Tara Bancroft has maintained their neutral stance on FATE stock, giving a Hold rating on...

1M ago

FATE

Fate Therapeutics Announces Corporate Restructuring Plan

An update from Fate Therapeutics ( ($FATE) ) is now available. On August 7, 2025, Fate Therapeutics‘ Board...

1M ago

FATE

Fate Therapeutics reports Q2 EPS (29c), consensus (34c)

Reports Q2 revenue $1.91M, consensus $1.14M. “We begin the second half of the year with meaningful progress across...

1M ago

FATE

Fate Therapeutics’ Phase 1 Study: A New Hope for Autoimmune Diseases

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is conducting a...

2M ago

FATE

Cautious Outlook on Fate Therapeutics Amid Promising Data and Safety Concerns

In a report released today, Robert Burns from H.C. Wainwright reiterated a Hold rating on Fate Therapeutics, with...

3M ago

FATE

Cautious Hold on Fate Therapeutics: Promising Early Data for FT819 in Lupus, Awaiting Broader Evidence

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating yesterday. Gil...

3M ago

FATE

Cautious Hold Rating on Fate Therapeutics Amid Promising but Preliminary CAR-T Therapy Data

Analyst Yanan Zhu from Wells Fargo maintained a Hold rating on Fate Therapeutics (FATE – Research Report) and...

3M ago

FATE

Fate Therapeutics announces updated data for FT819

Fate Therapeutics (FATE) announced new and updated clinical data from the first five patients dosed with FT819 for...

3M ago

FATE

Fate Therapeutics Approves Key Proposals at Annual Meeting

Fate Therapeutics ( ($FATE) ) just unveiled an update. On May 29, 2025, Fate Therapeutics held its Annual...

4M ago

FATE

Fate Therapeutics price target lowered to $4 from $5 at Baird

Baird lowered the firm’s price target on Fate Therapeutics (FATE) to $4 from $5 and keeps a Neutral...

4M ago

FATE

FATE FAQ

What was Fate Therapeutics’s price range in the past 12 months?

Fate Therapeutics lowest stock price was $0.66 and its highest was $4.20 in the past 12 months.

What is Fate Therapeutics’s market cap?

Fate Therapeutics’s market cap is $110.23M.

When is Fate Therapeutics’s upcoming earnings report date?

Fate Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is in 42 days.

How were Fate Therapeutics’s earnings last quarter?

Fate Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.351 by $0.061.

Is Fate Therapeutics overvalued?

According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fate Therapeutics pay dividends?

Fate Therapeutics does not currently pay dividends.

What is Fate Therapeutics’s EPS estimate?

Fate Therapeutics’s EPS estimate is -0.3.

How many shares outstanding does Fate Therapeutics have?

Fate Therapeutics has 115,329,700 shares outstanding.

What happened to Fate Therapeutics’s price movement after its last earnings report?

Fate Therapeutics reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.351. Following the earnings report the stock price went up 20.213%.

Which hedge fund is a major shareholder of Fate Therapeutics?

Currently, no hedge funds are holding shares in FATE

Fate Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-52.11%

Trailing 12-Months

Asset Growth

-29.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fate Therapeutics

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cellular immunotherapies for cancer and immune disorders. The company specializes in the advancement of programmed cellular therapies, utilizing its proprietary induced pluripotent stem cell (iPSC) technology to produce off-the-shelf immune cells designed to target and destroy cancer cells. Fate Therapeutics operates in the biotechnology sector and is dedicated to creating transformative treatments that harness the power of the immune system.

Fate Therapeutics (FATE) Earnings & Revenues

Historic Earnings Reports

FATE Stock 12 Month Forecast

Average Price Target

$4.21

▲(343.16% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.03,1.4892307692307694,1.9484615384615385,2.407692307692308,2.8669230769230767,3.3261538461538462,3.785384615384616,4.2446153846153845,4.703846153846154,5.163076923076924,5.622307692307692,6.081538461538462,6.540769230769231,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.03,1.2746153846153847,1.5192307692307692,1.7638461538461538,2.0084615384615385,2.253076923076923,2.497692307692308,2.7423076923076923,2.986923076923077,3.2315384615384612,3.4761538461538457,3.72076923076923,3.9653846153846155,{"y":4.21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.03,1.1046153846153846,1.1792307692307693,1.2538461538461538,1.3284615384615384,1.403076923076923,1.4776923076923076,1.5523076923076924,1.626923076923077,1.7015384615384614,1.7761538461538462,1.8507692307692307,1.9253846153846155,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.68,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >